» Articles » PMID: 29805648

Clinical, Pathological and Genetic Features of Anaplastic and Poorly Differentiated Thyroid Cancer: A Single Institute Experience

Abstract

Anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC) are very aggressive cancers whose histological diagnosis is not always straightforward. Clinical, pathological and genetic features may be useful to improve the identification of these rare histotypes. In the present study the clinical, pathological and genetic features of two groups of ATC (n=21) and PDTC (n=21) patients were analyzed. Clinical data were retrieved from a computerized database. The oncogenic profiles were studied using the Sanger sequencing method of a selected series of oncogenes and/or tumor suppressor genes known to be altered in these tumors. The presence of macrophages in both series of tissues was evaluated by immunohistochemistry. Patients with ATC were older and affected by a more advanced disease at diagnosis than those with PDTC. The median survival was significantly shorter in ATC compared with PDTC patients (P=0.0014). ATC showed a higher prevalence of and mutations (10/21, 47.6% and 9/21, 42.8%, respectively) while and mutations were the most prevalent in the PDTC group (7/21, 33.3% and 4/23, 19% respectively). Genetic heterogeneity (i.e., >2 mutations) was more frequent in ATC (10/21, 28.6%) compared with in PDTC (3/21, 4.7%) (P=0.03). Macrophages were more frequently present in ATC, particularly in those cases with mutations. In conclusion, these data indicate that ATC and PDTC may be characterized by different clinical, pathological and genetic profiles. In particular ATC, but not PDTC, were positive for and alterations. Complex mutations were also found in ATC but not in PDTC. Moreover, genetic heterogeneity was more frequent in ATC than PDTC. Finally, mutation and the accumulation of several mutations correlated with a shorter survival time.

Citing Articles

Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.

Valerio L, Matrone A Explor Target Antitumor Ther. 2025; 6:1002291.

PMID: 40061140 PMC: 11886382. DOI: 10.37349/etat.2025.1002291.


Validation of two predictive models for survival in anaplastic thyroid cancer (ATC).

Kasmann L, Nieto A, Rennollet R, Gurtner R, Oliinyk D, Augustin T BMC Cancer. 2024; 24(1):1477.

PMID: 39614234 PMC: 11606035. DOI: 10.1186/s12885-024-13217-2.


Aggressive Types of Malignant Thyroid Neoplasms.

Boudina M, Zisimopoulou E, Xirou P, Chrisoulidou A J Clin Med. 2024; 13(20).

PMID: 39458070 PMC: 11508432. DOI: 10.3390/jcm13206119.


Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature.

Casalini R, Romei C, Ciampi R, Ramone T, Prete A, Gambale C Endocrine. 2024; 87(1):243-251.

PMID: 39179735 DOI: 10.1007/s12020-024-03990-2.


An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Karimi Behnagh A, Eghbali M, Abdolmaleki F, Ghadikolaei O, Asl P, Afsharpad M Iran J Public Health. 2024; 53(7):1496-1507.

PMID: 39086414 PMC: 11287593. DOI: 10.18502/ijph.v53i7.16044.


References
1.
Ho Y, Tseng S, Chin T, Hsieh L, Lin J . p53 gene mutation in thyroid carcinoma. Cancer Lett. 1996; 103(1):57-63. DOI: 10.1016/0304-3835(96)04196-1. View

2.
Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti M . Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 1993; 91(4):1753-60. PMC: 288155. DOI: 10.1172/JCI116385. View

3.
Nagaiah G, Hossain A, Mooney C, Parmentier J, Remick S . Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011; 2011:542358. PMC: 3136148. DOI: 10.1155/2011/542358. View

4.
Nikiforov Y . Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2005; 15(4):319-27. DOI: 10.1385/ep:15:4:319. View

5.
Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384(9940):319-28. PMC: 4366116. DOI: 10.1016/S0140-6736(14)60421-9. View